GlaxoSmithKline (GSK) has made a serious play for the lucrative rheumatoid arthritis (RA) drug market, announcing the beginning of a phase 3 development programme, involving a new class of
The charity Parkinson’s UK has struck a £1 million partnership with NRG Therapeutics to develop drugs targeted at mitochondria that could protect cells producing dopamine, which have been d
UK biotech Oxford Biomedica and Japan’s Santen have begun an option and licence agreement to research and develop gene therapy products for an inherited retinal disease.
Sanifit has raised €72.2 million ($80.9m) in Spain’s largest private biotech fundraiser to finance phase 3 clinical development of its rare disease drug SNF472.
Sanofi’s Genzyme unit has handed back rights to two neurology gene therapies to US biotech Voyager Therapeutics, as part of a rethink of the companies’ joint research.